News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Mulls Killing GlaxoSmithKline’s Avandia Safety Study
April 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators are considering ending a safety study on GlaxoSmithKline's (GSK.L) diabetes drug Avandia, the Wall Street Journal reported on Sunday, saying the move could also jeopardize the drug's presence in the U.S market.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
FDA
Approvals
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
November 12, 2025
·
1 min read
·
Heather McKenzie
FDA
FDA Stalwart Pazdur Named Tidmarsh’s Replacement as CDER Director
November 11, 2025
·
1 min read
·
Heather McKenzie
Cardiovascular disease
Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025
November 11, 2025
·
5 min read
·
Tristan Manalac
Depression
Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss
November 11, 2025
·
2 min read
·
Tristan Manalac
